Top

Archives of Gynecology and Obstetrics

Published in:

01-07-2009 | Original Article

Prognostic significance of molecular classification of breast invasive ductal carcinoma

Authors: Mar Muñoz, M. Jesús Fernández-Aceñero, Silvia Martín, José Schneider

Published in: Archives of Gynecology and Obstetrics | Issue 1/2009

Abstract

Objective

Breast carcinoma classification has dramatically changed in recent years following application of molecular techniques. Immunohistochemistry can help select patients for different therapies. The objective of the present report is to determine the prognostic influence of the molecular classification of breast carcinoma with immunohistochemistry.

Materials and methods

We have retrospectively selected a cohort of 257 patients with invasive ductal carcinoma NOS diagnosed and treated in the same hospital between 1997 and 2000. We have classified the cases in four tumor types according to the immunohistochemical expression of several markers, as luminal A tumors [estrogen and/or progesterone receptors (ER/PE) positive and Her-2 negative]; luminal B tumors (ER/PR positive and Her-2 positive); Her-2 positive tumors (ER/PR negative with Her-2 positive); and triple negative phenotype (all markers negative).

Results

In our series, 116 patients had tumors of luminal A type (47.93%); 67 (27.68%) were luminal type B; 33 (13.63%) were Her2 positive; and 26 (10.74%) were triple negative. The recurrence rate was 19% for luminal type A tumors, 25.4% for luminal type B, 39.4% for Her2 positive and 30.8% for triple negative lesions. The mean relapse free survival was 79.07, 73.07, 64.3 and 83,5 months for luminal A and B, Her-2 and triple negative lesions, respectively. Mortality rate reached 11.2% for luminal A tumors compared with 19.4, 33.3 and 26.9% for luminal B, Her2 and triple negative tumors, respectively. The mean overall survival for these groups was 88.42, 81.41, 77.62 and 93.6 months.

Conclusion

Molecular classification with immunohistochemistry behaves as a significant prognosticator for breast invasive ductal carcinoma in our series of patients. The worse prognosis observed for Her2 expressing lesions may have changed after trastuzumab use.

Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168–183PubMedCrossRef

Nishimura R, Okumura Y, Arima N (2008) Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer 15:57–64. doi:10.1007/s12282-007-0014-z PubMedCrossRef

Olver IN (2008) Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when. Future Oncol 4:125–131. doi:10.2217/14796694.4.1.125 PubMedCrossRef

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenchikov A, Williams C, Zhu SX, Lonning PE, Borresen AL, Brown PO, Botstein D (2000) Molecular portraits of human tumours. Nature 406:747–752. doi:10.1038/35021093 PubMedCrossRef

Van`t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Meterse HL, van der Kooy K, Marton MJ, Witteveeen AT, Schreiber GJ, Kerkhoven RM, Roberts C (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi:10.1038/415530a CrossRef

Schneider J, Tejerina Gómez A, Sánchez J, Perea C, Tejerina Bernal A, Lucas AR (2007) Molecular subgroups of small (pT1) breast carcinomas belonging exclusively to the ductal infiltrating variety. Cancer Genomics Proteomics 4:399–402PubMed

Fdez-Aceñero MJ, Fariña J, Galindo M, Aragoncillo P (1998) Vascular enumeration as a significant prognosticator for invasive breast carcinoma. J Clin Oncol 16:1684–1688

Finetti J, Cervera N, Charafe E, Chabannon C, Charpin C, Chaffanet M, Jacquemier J, Viens P, Birnbaum D, Bertucci F (2008) Sixteen kinase gene expression identifies luminal breast cancer with poor prognosis. Cancer Res 68:767–776. doi:10.1158/0008-5472.CAN-07-5516 PubMedCrossRef

Goldstein NS, Decker D, Severson D, Schell S, Vicini F, Margolis J, Dekhne NS (2007) Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 110:1687–1696. doi:10.1002/cncr.22981 PubMedCrossRef

10.

Tang P, Wang P, Bourne P (2008) Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol 39:506–513. doi:10.1016/j.humpath.2007.09.005 PubMedCrossRef

11.

Rakha EA, El-Sayed ME, Green AR, Lee AHS, Robertson JF, Ellis IO (2007) Prognostic markers in triple negative breast cancer. Cancer 109:25–32. doi:10.1002/cncr.22381 PubMedCrossRef

12.

Lohrisch C, Piccart M (2001) Her2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2:129–135. doi:10.3816/CBC.2001.n.017 PubMedCrossRef

13.

Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J (2000) The prognostic value of p53 and c-erbB2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factor in 613 patients with a follow up of 14–30 years. Cancer 88:804–813. doi:10.1002/(SICI)1097-0142(20000215)88:4<804::AID-CNCR11>3.0.CO;2-YPubMedCrossRef

14.

van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Köchli OR, Mross F, Dieterich H, Seitz R, Ross D, Botstein D, Brown P (2002) Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991–1996PubMed

Title: Prognostic significance of molecular classification of breast invasive ductal carcinoma
Authors: Mar Muñoz
M. Jesús Fernández-Aceñero
Silvia Martín
José Schneider
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 1/2009
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-008-0867-1

At a glance: The STEP trials

Springer Medicine

Prognostic significance of molecular classification of breast invasive ductal carcinoma

Abstract

Objective

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2009

Multiple vaginal mullerian cysts: a case report and review of literature

An unusual case of recurrent endometrial cancer presented with isolated cervical lymph node metastasis

Laparoscopic partial cystectomy for bladder endometriosis

Secondary involvement of the breast in T-cell non-Hodgkin lymphoma, an unusual example mimicking inflammatory breast carcinoma

When should we perform prophylactic antibiotics in elective cesarean cases?

Is oligohydramnios more common during the summer season?